All In Biotech

Drug Trial Radar · NCT06482437

Safety and Efficacy of NMD670 in Adult Patients With Type 1 and Type 2 Charcot-Marie-Tooth Disease

A Phase 2a, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of NMD670 Over 21 Days in Ambulatory Adult Patients With Type 1 and Type 2 Charcot-Marie-Tooth Disease

Last checked: Nov 19, 2026Latest source record: Nov 12, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

81

Actual

Start

Sep 30, 2024

Primary completion

Oct 28, 2025

Study completion Nov 4, 2025

Sponsor

Lead sponsor
NMD Pharma A/SIndustry
Sponsor type
Industry
First posted
Jul 1, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Phase 2a study aims to evaluate the efficacy, safety and tolerability of NMD670 vs placebo administered twice a day (BID) for 21 days in ambulatory adult patients with Charcot-Marie-Tooth disease type 1 and type 2.

Conditions

  • Charcot-Marie-Tooth Disease

Interventions

  • NMD670Drug

    Tablets taken twice daily for 21 days

  • PlaceboDrug

    Tablets taken twice daily for 21 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline to day 21 in 6-minute walk test total distance for NMD670 vs placeboTime frame: Baseline to day 21

Locations

19 sites in 5 countries. Site status is shown where the registry gives one.

  • University of Kansas Medical Center, Department of Neurology

    Kansas City, Kansas

  • Mass General Neurology

    Boston, Massachusetts

  • NextGen Precision Health

    Columbia, Missouri

  • Columbia University Medical Center

    New York, New York

  • University of Rochester Neuromuscular Disease Center

    Rochester, New York

  • OSU Department of Neurology Division of Neuromuscular Diseases

    Columbus, Ohio

  • National Neuromuscular research Institute, PLLC

    Austin, Texas

  • Providence Medical Research Center

    Spokane, Washington

  • University Hospitals Leuven, Department of Neurology

    Leuven, Belgium

  • CHR de la Citadelle- Site Citadelle Neurolgie Boulevard du 12eme de Ligne 1

    Liège, Belgium

  • Aarhus University Hospital

    Aarhus, Denmark

  • Rigshospitalet, Department of Neurology

    Copenhagen, Denmark

  • CHU Marseille, Reference centre for neuromuscular diseases and ALS Department of Neuromuscular Diseases

    Marseille, France

  • Laboratoire d'Explorations Fonctionnelles, CHU Nantes

    Nantes, France

  • Centre Hospitalier Universitaire De Nice

    Nice, France

  • Institut de Myologie Groupe Hospitalier Pitié-Salpêtrière

    Paris, France

  • Bicêtre University Hospital

    Paris, France

  • Hospital Universitari Vall d'Hebron

    Barcelona, Spain

  • Hospital Universitari i Politecnic La Fe de Valencia

    Valencia, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.